Cited by 544Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.

Turning cold tumors hot: from molecular mechanisms to clinical applications

Zhang, Jiahui, Huang, Di, Saw, Phei Er, Song, Erwei·2022·Trends in Immunology

DOI 10.1016/j.it.2022.04.010

Open this paper in CoChat — free account

Abstract

Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most 'immune-cold' solid tumors are not responsive. The diversity of immune evasion mechanisms remains a key obstacle in turning nonresponsive 'cold' tumors into responsive 'hot' ones. Therefore, exploring the mechanisms of such transitions and tumor immunotyping can provide significant insights into designing effective therapeutic strategies against cancer. Here, we focus on the latest advances regarding local and systemic regulatory mechanisms of immune responses in cold and hot tumors. We also highlight the necessity for tumor immunotyping through the assessment of multiple immunological variables using various diagnostic techniques and biomarkers. Finally, we discuss the challenges and potential clinical applications of immunophenotyping to turn cold tumors hot, which may further guide combined immunotherapies.

Integrity signals

Registry

Crossref · 10.1016/j.it.2022.04.010

Cites

189 of 189 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED ARTICLE: Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression
Kamiya, A., Hayama, Y., Kato, S., Shimomura, A., Shimomura, T., Irie, K., Kaneko, R., Yanagawa, Y., Kobayashi, K., & Ochiya, T. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0430-3 · Cited by 288
Retracted
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Self-citation
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citation

Show all 189 references

Sorted by citations

Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811
CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential
Koh, C., Lee, S., Kwak, M., Kim, B., & Chung, Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01105-x · Cited by 379
“These “ hot ” tumors exhibit a more favorable response to immunotherapies than “ cold ” tumors, which lack Tc1 cell in ﬁ ltration 28,29 .”
Background
Tertiary lymphoid structures in anticancer immunity
Teillaud, J., Houel, A., Panouillot, M., Riffard, C., & Dieu‐Nosjean, M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00728-0 · Cited by 322
“Finally, it is unclear whether ‘cold’ tumours that do not exhibit substantial immune cell infiltrates could be made ‘hot’ when using inducers of TLS 189 .”
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
Huang, D., Zhu, X., Ye, S., Zhang, J., Liao, J., Zhang, N., Zeng, X., Wang, J., Yang, B., Zhang, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06834-7 · Cited by 222
Self-citation
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer
Chen, Y., Wang, D., Li, Y., Lu, Q., Si, W., Bo, Y., Chen, X., Ye, Z., Fan, H., Liu, B., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.009 · Cited by 229
Photon-Controlled Pyroptosis Activation (PhotoPyro): An Emerging Trigger for Antitumor Immune Response
Li, M., Kim, J., Rha, H., Son, S., Levine, M. S., Xu, Y., Sessler, J. L., & Kim, J. S. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01231 · Cited by 183
Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion
Zhu, Y., Zhou, Z., Du, X., Lin, X., Liang, Z.-M., Chen, S., Sun, Y., Wang, Y., Na, Z., Wu, Z., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.015 · Cited by 200
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 200
“Notably, the WNT pathway inversely correlates with the skewing of the TCR repertoire, whereas immune-inflamed tumors are characterized by high TCR clonality independent of GI [22].”
Background
Reactive oxygen species-powered cancer immunotherapy: Current status and challenges
He, M., Wang, M., Xu, T., Zhang, M., Dai, H., Wang, C., Ding, D., & Zhong, Z. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.040 · Cited by 147
Medicinal plant-derived mtDNA via nanovesicles induces the cGAS-STING pathway to remold tumor-associated macrophages for tumor regression
Liu, J., Xiang, J., Jin, C., Ye, L., Wang, L., Gao, Y., Lv, N., Zhang, J., You, F., Qiao, H., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01835-0 · Cited by 132
“phenotype Since the properties of tumor microenvironment (TME), immune-tolerant (“cold”) or immunogenic (“hot”) [28], have a determinative role in cancer initiation Fig.”
BackgroundSelf-citation
Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma
Sun, K., Zhang, X., Shi, J., Huang, J., Wang, S., Li, X., Lin, H., Zhao, D., Ye, M., Zhang, S., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci187024 · Cited by 138
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 123
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Niu, M., Yi, M., Wu, Y., Lyu, L., He, Q., Yang, R., Zeng, L., Shi, J. Y., Zhang, J., Zhou, P., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01487-5 · Cited by 110
“Most ‘immune-cold’ tumors are resistant to PD-1/PD-L1 antibodies [54].”
BackgroundSelf-citation
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00352-w · Cited by 120
“Primary resistance frequently occurs in so-called “cold tumors”, characterized by low antigenicity, minimal or absent T cell infiltration, and an immunosuppressive microenvironment, resulting in poor responsiveness [77].”
Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer
Murayama, T., Nakayama, J., Jiang, X., Miyata, K., Morris, A. D., Cai, K. Q., Prasad, R. M., Ma, X., Efimov, A., Belani, N., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0486 · Cited by 112
“…immunity in cancer cells is a potent means by which cold (“immune-desert” or “immune-excluded”) tumors can be turned hot (“immune-inflamed,” in which T cells and other immune cells are positioned near the tumor cells), enhancing responsiveness to immune-checkpoint blockade (ICB) therapies (1–5).”
Enhancing immuno-oncology investigations through multidimensional decoding of tumor microenvironment with IOBR 2.0
Zeng, D., Fang, Y., Qiu, W., Luo, P., Wang, S., Shen, R., Gu, W., Huang, X., Mao, Q., Wang, G., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100910 · Cited by 111
Tetrahedral DNA Nanostructure with Interferon Stimulatory DNA Delivers Highly Potent Toxins and Activates the cGAS‐STING Pathway for Robust Chemotherapy and Immunotherapy
Zhang, L., Wang, Y., Karges, J., Tang, D., Zhang, H., Zou, K., Song, J., & Xiao, H. (2022) · Advanced Materials · doi:10.1002/adma.202210267 · Cited by 99
Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications
Wu, P., Han, J., Gong, Y., Liu, C., Yu, H., & Xie, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101990 · Cited by 99
“regulate the response of the immune system to cancer cells in recent years (Figure 1) [9].”
Background
Polymeric nanoparticle-based nanovaccines for cancer immunotherapy
Zhang, Y., Chen, J., Shi, L., & Ma, F. (2022) · Materials Horizons · doi:10.1039/d2mh01358d · Cited by 96
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
Yin, J., Yuan, J., Li, Y., Fang, Y., Wang, R., Jiao, H., Tang, H., Zhang, S., Lin, S., Feng, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02469-3 · Cited by 97
T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution
Yang, W., Liu, S., Mao, M., Gong, Y., Li, X., Lei, T., Liu, C., Wu, S., & Hu, Q. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02960-w · Cited by 95
“We then summarized the genes, cytokines, and chemokines involved in this process and elaborated on their potential as prognostic biomarkers and therapeutic targets [133, 134].”
Background
A Single‐Atom Manganese Nanozyme Mn‐N/C Promotes Anti‐Tumor Immune Response via Eliciting Type I Interferon Signaling
Qiao, W., Chen, J., Zhou, H., Hu, C., Dalangood, S., Li, H., Yang, D., Yang, Y. P., & Gui, J. (2024) · Advanced Science · doi:10.1002/advs.202305979 · Cited by 84
Zinc–Iron Bimetallic Peroxides Modulate the Tumor Stromal Microenvironment and Enhance Cell Immunogenicity for Enhanced Breast Cancer Immunotherapy Therapy
Lu, Y., Chen, Y., Hou, G., Lei, H., Liu, L., Huang, X., Sun, S., Liu, L., Liu, X., Na, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c12615 · Cited by 83
Cuproptosis-immunotherapy using PD-1 overexpressing T cell membrane-coated nanosheets efficiently treats tumor
Liu, T., Zhou, Z., Zhang, M., Lang, P., Li, J., Liu, Z., Zhang, Z., Li, L., & Zhang, L. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.055 · Cited by 80
Alendronate Triggered Dual‐Cascade Targeting Prodrug Nanoparticles for Enhanced Tumor Penetration and STING Activation of Osteosarcoma
Shen, M., Wang, Y., Bing, T., Tang, Y., Liu, X., & Yu, Y. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202307013 · Cited by 78
The molecular classification of cancer‐associated fibroblasts on a pan‐cancer single‐cell transcriptional atlas
Chen, B., Chan, W. N., Xie, F., Mui, C. W., Liu, X., Cheung, A. H. K., Lung, R. W. M., Chow, C., Zhang, Z., Fang, C., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1516 · Cited by 80
“71,72 Our study contributes a novel perspective on assessing immunotherapy sensitivity in solid tumours by analysing the proportion of iCAFs.”
Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer
Qian, X., Huang, Y., Ye, Z., Gao, B., Qian, Z., Ding, Y., Mao, Z., Du, Y., & Wang, W. (2024) · ACS Nano · doi:10.1021/acsnano.4c02947 · Cited by 79
Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies
Shah, D. D., Chorawala, M. R., Raghani, N. R., Patel, R., Fareed, M., Kashid, V. A., & Prajapati, B. G. (2025) · Medical Oncology · doi:10.1007/s12032-025-02641-4 · Cited by 86
“The absence of significant immune cell infiltration in immune cold tumors hinders the recognition of tumor cells by the immune system, leading to reduced efficacy of immunotherapies that rely on immune activation [187].”
The future of affordable cancer immunotherapy
Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 81
Immunogenic cell death in cancer immunotherapy
Choi, M., Shin, J., Lee, C.-E., Chung, J.-Y., Kim, M., Yan, X., Yang, W., & Cha, J. (2023) · BMB Reports · doi:10.5483/bmbrep.2023-0024 · Cited by 79
“gists pay attention to the transition of cold tumors into hot tumors before T-cell therapy (4, 5).”
Background
Biomimetic Nanomodulators With Synergism of Photothermal Therapy and Vessel Normalization for Boosting Potent Anticancer Immunity
Lan, J., Zeng, R., Li, Z., Yang, X., Liu, L., Chen, L., Sun, L., Shen, Y., Zhang, T., & Ding, Y. (2024) · Advanced Materials · doi:10.1002/adma.202408511 · Cited by 75
Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy
Yang, M., Zhou, J., Lu, L., Deng, D., Huang, J., Tang, Z., Shi, X., Lo, P., Lovell, J. F., Zheng, Y., et al. (2024) · Exploration · doi:10.1002/exp.20230171 · Cited by 74
Peptide‐Driven Proton Sponge Nano‐Assembly for Imaging and Triggering Lysosome‐Regulated Immunogenic Cancer Cell Death
He, T., Wen, J., Wang, W., Hu, Z., Ling, C., Zhao, Z., Cheng, Y., Chang, Y., Xu, M., Jin, Z., et al. (2024) · Advanced Materials · doi:10.1002/adma.202307679 · Cited by 69
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
Peyraud, F., Guégan, J., Vanhersecke, L., Brunet, M., Teyssonneau, D., Palmieri, L., Bessede, A., & Italiano, A. (2025) · Med · doi:10.1016/j.medj.2024.10.023 · Cited by 71
Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
Zheng, Y., Li, S., Tang, H., Meng, X., & Zheng, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1153990 · Cited by 68
Tryptophan 2,3‐dioxygenase‐positive matrix fibroblasts fuel breast cancer lung metastasis via kynurenine‐mediated ferroptosis resistance of metastatic cells and T cell dysfunction
Liu, Y., Chen, S.-C., Wan, X., Wang, R., Luo, H., Chang, C., Dai, P., Gan, Y., Guo, Y., Hou, Y., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12608 · Cited by 61
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment
Li, M., Jiang, P., Yang, Y., Xiong, L., Wei, S., Wang, J., & Li, C. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00464-5 · Cited by 65
“Immunotherapy has been shown to function as a tumor suppressor in various tumors such as melanoma [187], non-small cell lung cancer [188], and bladder cancer [189].”
Background
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 61
Beyond Drug Delivery System: Immunomodulatory Layered Double Hydroxide Nanoadjuvants Take an Essential Step Forward in Cancer Immunotherapy
Zhu, C., Jiang, J., Jia, Y., Xu, Z. P., & Zhang, L. L. (2023) · Accounts of Materials Research · doi:10.1021/accountsmr.3c00094 · Cited by 55
Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy
Bie, N., Yong, T., Wei, Z., Liang, Q., Zhang, X., Li, S., Li, X., Li, J., Gan, L., & Yang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01658-3 · Cited by 53
Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity
Liu, L., Li, S., Qu, Y., Bai, H., Pan, X., Wang, J., Wang, Z., Duan, J., Zhong, J., Wan, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101206 · Cited by 54
“2 Here, we showed that ERO1A reshapes the TME to drive persistent immunosuppression maintained by the ER stress response, thus affecting immune context and response to PD-1 blockade.”
Background
Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
Vryza, P., Fischer, T., Mistakidi, E., & Zaravinos, A. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101788 · Cited by 55
“Growing evidence suggests that targeting MDSCs therapeutically can attenuate their tumor-promoting functions and immunosuppressive activities, thus enhancing the effectiveness of checkpoint inhibitors [137].”
Background
Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment
Yu, X., Liu, R., Gao, W., Wang, X., & Zhang, Y. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00450-z · Cited by 52
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer
Wu, F., Wang, M., Zhong, T., Xiao, C., Chen, X., Huang, Y., Wu, M., Yu, J., & Chen, D. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00428-9 · Cited by 48
Integrated bulk and single-cell transcriptomes reveal pyroptotic signature in prognosis and therapeutic options of hepatocellular carcinoma by combining deep learning
Liu, Y., Li, H., Zeng, T., Wang, Y., Zhang, H., Wan, Y., Shi, Z., Cao, R., & Tang, H. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad487 · Cited by 50
Intratumoral CD103 + CD8 + T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma
Ren, S., Lan, T., Wu, F., Chen, S., Jiang, X., Huo, C., Li, Z., Xie, S., Wu, D., Wang, R., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12480 · Cited by 50
“Although CPS is an evaluating method with a high predictive value of improved survival across solid tumors [3, 34], its performance in predicting the responses of NACI treatments remains unclear especially in the case of advanced HNSCC.”
BackgroundMethod
Free Radicals Generated in Perfluorocarbon–Water (Liquid–Liquid) Interfacial Contact Electrification and Their Application in Cancer Therapy
Li, H., Wang, Z., Chu, X., Zhao, Y., He, G., Hu, Y., Liu, Y., Wang, Z. L., & Jiang, P. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c02149 · Cited by 48
Immunotherapy in breast cancer: current landscape and emerging trends
Ran, R., Chen, X., Yang, J., & Xu, B. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00667-y · Cited by 60
Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy
He, Y., Huang, J., Li, Q., Xia, W., Zhang, C., Liu, Z., Xiao, J., Yi, Z., Deng, H., Xiao, Z., et al. (2022) · Cancers · doi:10.3390/cancers14215317 · Cited by 47
TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress
Shen, X., Zhou, S., Yang, Y., Tu, H., Xiang, Z., Zhao, J., Zhu, C., Zeng, L., & Zhang, L. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1034842 · Cited by 44
Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy
Zhang, P., Zhong, D., Yu, Y., Wang, L., Li, Y., Liang, Y., Shi, Y., Duan, M., Li, B., Niu, H., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122695 · Cited by 44
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells
Wen, Y., Xia, Y., Yang, X., Li, H., & Gao, Q. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.01.001 · Cited by 44
Engineered NanoAlum from aluminum turns cold tumor hot for potentiating cancer metalloimmunotherapy
Jia, Y., Hu, J., Zhu, C., Li, Z., Yang, X., Liu, R., Zeng, L., & Zhang, L. L. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.043 · Cited by 46
The enrichment of the gut microbiota Lachnoclostridium is associated with the presence of intratumoral tertiary lymphoid structures in hepatocellular carcinoma
Zhao, R., Li, J., Chen, B., Zhao, J., Hu, L., Huang, K., Chen, Q., Yao, J., Lin, G., Bao, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1289753 · Cited by 43
Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction
Bernatowicz, K., Amat, R., Prior, O., Frigola, J., Ligero, M., Grussu, F., Zatse, C., Serna, G., Nuciforo, P. G., Toledo, R. A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009140 · Cited by 49
Atypical chemokine receptors: emerging therapeutic targets in cancer
Torphy, R. J., Yee, E. J., Schulick, R. D., & Zhu, Y. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.09.009 · Cited by 43
T cell exhaustion in human cancers
Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 49
Engineering metal‐phenolic networks for enhancing cancer therapy by tumor microenvironment modulation
Xie, L., Li, J., Wang, L., & Dai, Y. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1864 · Cited by 41
Comprehensive characterization of tumor microenvironment in colorectal cancer via molecular analysis
Wu, X., Yan, H., Qiu, M., Qu, X., Wang, J., Xu, S., Zheng, Y., Ge, M., Yan, L., & Li, L. (2023) · eLife · doi:10.7554/elife.86032 · Cited by 45
Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
Xiang, D., Han, X.-L., Li, J., Zhang, J., Xiao, H., Li, T., Zhao, X., Xiong, H., Xu, M., & Bi, W. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100675 · Cited by 41
Self-citation
Intimate communications within the tumor microenvironment: stromal factors function as an orchestra
Cheng, B., Yu, Q., & Wang, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-022-00894-z · Cited by 43
“regulating stromal and immune cells via multiple mechanisms [91].”
Background
Low-intensity focused ultrasound targeted microbubble destruction reduces tumor blood supply and sensitizes anti-PD-L1 immunotherapy
Wu, N., Cao, Y., Liu, Y., Zhou, Y., He, H., Tang, R., Wan, L., Wang, C., Xiong, X., Zhong, L., et al. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1173381 · Cited by 37
“Nevertheless, the overall response rate of checkpoint inhibition strategies is limited to 20%-30% in clinical practice because most “immune-cold” solid tumors are not responsive, which are characterized by the lack of intratumoral T cell infiltration or signals to stimulate T cell activation (Li et al., 2018; Bagchi e…”
Background
Supplementation with a high-glucose drink stimulates anti-tumor immune responses to glioblastoma via gut microbiota modulation
Kim, J.-H., Kim, Y., La, J., Park, W. H., Kim, H.-J., Park, S. H., Ku, K. B., Kang, B. H., Lim, J., Kwon, M. S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113220 · Cited by 39
Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer
Jiang, Y., Zheng, Y., Zhang, Y., Kong, S., Dong, J., Wang, F., Ziman, B., Gery, S., Hao, J., Zhou, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46785-9 · Cited by 37
“In particular, patients who display an “ immune-cold ” immunophenotype (limited intra-tumoral in ﬁ ltration of immune cells) are often nonresponsive or resistant to anti-PD-1/PD-L1 agents 13 – 15 .”
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial
Tian, X., Cai, J., Xia, Y., Zhang, Y., Wang, L., Liu, P., Huang, H., Li, Y., Zhou, H., Li, Z., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00066-8 · Cited by 37
Bacteria-driven nanosonosensitizer delivery system for enhanced breast cancer treatment through sonodynamic therapy-induced immunogenic cell death
Du, M., Wang, T., Peng, W., Feng, R., Goh, M., & Chen, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02437-0 · Cited by 36
Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism
Tang, R., Zhang, Z., Liu, X., Liao, Y., Chen, Y., Xiao, M., Li, Y., Zhou, C., Tan, Z., Zhang, C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.019 · Cited by 36
Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma
Melo-Alvim, C., Neves, M. E., Santos, J. L., Abrunhosa-Branquinho, A. N., Barroso, T., Costa, L., & Ribeiro, L. (2022) · Diagnostics · doi:10.3390/diagnostics13010099 · Cited by 35
“This combination can be useful for locally advanced disease and metastatic disease, especially if limited oligoprogression is observed while on isolated immunotherapy, promoting the so-called “turning cold tumor to hot tumor” effect [35].”
Background
Infiltration characteristics and regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment
Ouyang, P., Zhang, J., He, X., Yang, C., Zeng, D., & Xu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1661545 · Cited by 44
Self-citation
Systemic Delivery of mPEG‐Masked Trispecific T‐Cell Nanoengagers in Synergy with STING Agonists Overcomes Immunotherapy Resistance in TNBC and Generates a Vaccination Effect
Shen, M., Chen, C., Guo, Q., Wang, Q., Liao, J., Wang, L., Yu, J. Y., Xue, M., Duan, Y., & Zhang, J. (2022) · Advanced Science · doi:10.1002/advs.202203523 · Cited by 34
Self-citation
Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity
Kang, S., Mansurov, A., Kurtanich, T. R., Chun, H. R., Slezak, A. J., Volpatti, L. R., Chang, K., Wang, T., Alpar, A. T., Refvik, K. C., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh9879 · Cited by 34
Nanomaterials: leading immunogenic cell death-based cancer therapies
Ma, C., Cheng, Z., Tan, H., Wang, Y., Sun, S., Zhang, M., & Wang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447817 · Cited by 38
“Reversing immunode ﬁ cient “ cold tumors ” to immunogenic “ hot tumors ” is challenging to achieving maximum therapeutic bene ﬁ t (53, 54).”
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Middelburg, J., Sluijter, M., Schaap, G., Göynük, B., Lloyd, K. A., Ovcinnikovs, V., Zom, G. G., Marijnissen, R. J., Groeneveldt, C., Griffioen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44308-6 · Cited by 32
“This ismostprominent in immunologically ‘ cold ’ tumors, which hardly exhibit any T-cell in ﬁ ltrate 7 .”
Unraveling the role of M1 macrophage and CXCL9 in predicting immune checkpoint inhibitor efficacy through multicohort analysis and single‐cell RNA sequencing
Yu, Y., Chen, H., Ouyang, W., Zeng, J., Huang, H., Mao, L., Jia, X., Guan, T., Wang, Z., Lin, R., et al. (2024) · MedComm · doi:10.1002/mco2.471 · Cited by 32
Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy
Wang, H., Zhan, H., Pan, B., Zeng, L., Chen, Z., Liu, S., Zhang, Q., Hong, X., Lu, J., Lin, X., et al. (2025) · Advanced Materials · doi:10.1002/adma.202501565 · Cited by 33
Combining precision oncology and immunotherapy by targeting the MALT1 protease
Mempel, T. R., & Krappmann, D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005442 · Cited by 31
Tumor-targeting hydroxyapatite nanoparticles for remodeling tumor immune microenvironment (TIME) by activating mitoDNA-pyroptosis pathway in cancer
Yang, Y., Yang, J., Zhu, N., Qiu, H., Feng, W., Chen, Y., Chen, X., Chen, Y., Zheng, W., Liang, M., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02231-4 · Cited by 33
“…subset of patients can benefit from immunotherapy, how to elicit immune responses specifically against tumor antigens within the body and thus transform a substantial portion of non-responsive “cold” tumor types into responsive “hot” tumor types remained an essential issue to be addressed [5–7].”
Background
Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
Yu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W. P., Chen, X., Wang, L., & Goh, B. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1261575 · Cited by 31
Tumor microenvironment-reprogrammable CpG-templated copper sulfide loaded with disulfiram for sensitized cuproptosis immunotherapy
Zhao, P., Wang, H., Zhao, H., Yin, C., Xing, Y., Wang, J., Chi, L., Ye, L., & Gu, W. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.150524 · Cited by 29
The circRNA cEMSY Induces Immunogenic Cell Death and Boosts Immunotherapy Efficacy in Lung Adenocarcinoma
Zhang, Y., Song, X., Feng, Y., Qian, Y., Chen, B., Zhang, T., Wang, H., Chen, Y., Yu, X., Ding, H., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1484 · Cited by 32
Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma
Shen, B., Zhang, G., Liu, Y., Wang, J., & Jiang, J. (2022) · Genes · doi:10.3390/genes13101834 · Cited by 28
“Nevertheless, the low-risk group is the immune “clod” phenotype, which features lower sensitivity to the immunotherapy of HCC patients [49].”
Background
Carboxymethylated Alginate-Resiquimod Micelles Reverse the Immunosuppressive Tumor Microenvironment and Synergistically Enhance the Chemotherapy and Immunotherapy for Gastric Cancer
Chen, J., Liu, X., Zhao, S., Chen, H., Lu, T., Wang, J., Han, J., Wu, W., Shen, X., & Li, C. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c06828 · Cited by 28
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8 + T cell infiltration and functional transition
Yu, A., Hu, J., Fu, L., Huang, G., Deng, D., Zhang, M., Wang, Y., Shu, G., Jing, L., Li, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007230 · Cited by 30
“63 65 67 Previous studies showed that high certain molecules (such as BCAT2, β -catenin, and FGFR3) expression in tumor tissues can significantly reduce the expression of chemokines/cytokines.”
Background
Synergizing CXCL9 with BRD4‐PROTAC Using Nanochaperone Boosts Robust T Cell‐Dependent Antitumor Immune Responses for Cancer Immunotherapy
Chen, J., Ma, F., Zhang, Y., Xu, M., Xu, L., Liu, Y., Ma, R., & Shi, L. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202314203 · Cited by 28
B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature
Mielcarska, S., Kot, A., Dawidowicz, M., Kula, A., Sobków, P., Kłaczka, D., Waniczek, D., & Świętochowska, E. (2025) · Cells · doi:10.3390/cells14151209 · Cited by 28
“Immune-cold tumors, characterized by a worse response to immune checkpoint blockade (ICB) therapies [23], feature a lowered density of tumor-infiltrating lymphocytes (TILs), elevated immunosuppressive properties of tumor microenvironment (TME), and, therefore, compromised capabilities of inducing…”
Focused acoustic vortex-mediated sonochemotherapy for the amplification of immunogenic cell death combined with checkpoint blockade to potentiate cancer immunotherapy
Ya, Z., Guo, S., Li, Y., Zhu, M., Zhang, L., Zong, Y., & Wan, M. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122278 · Cited by 27
Light‐Enhanced Hypoxia‐Responsive Gene Editing for Hypoxia‐Resistant Photodynamic and Immunotherapy
Qu, S., Ji, Y., Fan, L., Yan, T., Zhu, G., Song, H., Yang, K., & Han, X. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302615 · Cited by 26
The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer
Dou, T., Li, J., Zhang, Y., Pei, W., Zhang, B., Wang, B., Wang, Y., & Jia, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368687 · Cited by 29
Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study
Li, B., Xie, S., Han, J., Cao, H., Lin, Z., Hu, H., Pan, C., Li, Q., Li, J., Wang, L., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001891 · Cited by 27
Extracellular vesicles in cancer drug resistance: Mechanistic insights and therapeutic implications
Zuo, J., Yan, H., Qin, S., Yan, Y., Wang, S., Yang, L., Yang, J., & Yang, J. H. (2024) · MedComm – Oncology · doi:10.1002/mog2.94 · Cited by 26
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
Spagnolo, C. C., Giuffrida, G., Cannavò, S., Franchina, T., Silvestris, N., Ruggeri, R. M., & Santarpía, M. (2022) · Cancers · doi:10.3390/cancers15010246 · Cited by 28
Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone
Huang, R., Ning, Q., Zhao, J., Zhao, X., Zeng, L., Yi, Y., & Tang, S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.116006 · Cited by 25
NIR-715 photodynamic therapy induces immunogenic cancer cell death by enhancing the endoplasmic reticulum stress response
Zheng, Z.-Y., Lin, W., Su, J.-W., Huang, Q., Zhang, C., Pan, W.-X., Li, E., Zhang, H., & Xu, L. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07283-4 · Cited by 27
Tumor Immunophenotyping‐Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer
Wang, J., Qiu, Q., Zheng, Q., Zhao, Y., Xu, Y., Zhang, T., Wang, S., Wang, Q., Jin, Q., Ye, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202207417 · Cited by 24
Polyamine metabolism and anti-tumor immunity
Wu, J., Zeng, Y. J., You, Y.-Y., & Chen, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529337 · Cited by 25
Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells
Li, L., & Jensen, R. A. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0230 · Cited by 24
Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma
Li, L., Zeng, X., Chao, Z., Luo, J., Guan, W., Zhang, Q., Ge, Y., Wang, Y., Xiong, Z., Ma, S., et al. (2023) · Advanced Science · doi:10.1002/advs.202301975 · Cited by 23
Self-citation
Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer
Adzibolosu, N. K., Alvero, A. B., Ali‐Fehmi, R., Gogoi, R. P., Corey, L., Tedja, R., Chehade, H., Gogoi, V., Morris, R. T., Anderson, M. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204148 · Cited by 23
Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives
Pan, Y., Xue, X., & Liang, X. (2024) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300129 · Cited by 23
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Jiang, Z., Cai, G., Liu, H., Liu, L., Huang, R., Nie, X., Gui, R., Li, J., Ma, J., Cao, K., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02525-1 · Cited by 23
“Since ICB therapy has been found to rejuvenate CTLs in tumors [5], it seems reasonable to evaluate the efficacy of ICB therapy based on CD8 + T-cell infiltration.”
Background

Authors: Zhang, J., Huang, D., Saw, P. E., & Song, E.
Affiliations: Sun Yat-sen University (CN)
Corresponding author: Saw, Phei Er
Song, Erwei
ORCID: Zhang, Jiahui
Huang, Di
Saw, Phei Er
Song, Erwei
Venue: Trends in Immunology
Publisher: Elsevier BV
Published: 2022-07
Volume: 43
Issue: 7
Pages: 523-545
ISSN: 1471-4906 (ISSN-L)
DOI: 10.1016/j.it.2022.04.010
OpenAlex: W4281490788
Cited by: 534
References: 189
Citations by year: 2026: 72 · 2025: 145 · 2024: 162 · 2023: 133 · 2022: 22
FWCI: 14.42
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Trends in Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: National Natural Science Foundation of China (81621004, 81720108029, 81930081, 91940305, 92159303)
Guangdong Science and Technology Department (2020B1212030004, 2020B1212060018)
Guangzhou Municipal Science and Technology Bureau (20212200003)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cold tumors, immune evasion, immune checkpoint blockade, tumor microenvironment, immune regulation, biomarkers, combination immunotherapy, solid tumors
MeSH terms: Humans, Immunity, Immunotherapy, Neoplasms, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Turning cold tumors hot: from molecular mechanisms to clinical applications

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks